Mayne buys back US Doryx rights from Actavis for $50mm
Actavis PLC divested to Mayne Pharma Group Ltd. its US rights to the tetracycline antibiotic Doryx (delayed-release doxycycline) for severe acne. Mayne, which originally developed the drug, paid $50mm and also gets the product's trademark, marketing materials, inventory, and medical and technical data.
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com